Nexentis Technologies (80W0) Stock Overview

Through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. More details

80W0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 13.1% per year over past 5 years

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap (€3M)

Shareholders have been substantially diluted in the past year

80W0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Nexentis Technologies Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Nexentis Technologies
Historical stock prices
Current Share Price	US$3.50
52 Week High	US$3.75
52 Week Low	US$3.12
Beta	1.74
1 Month Change	2.94%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-6.67%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	80W0	DE Chemicals	DE Market
7D	2.9%	1.3%	1.6%
1Y	n/a	3.6%	2.2%

Return vs Industry: Insufficient data to determine how 80W0 performed against the German Chemicals industry.

Return vs Market: Insufficient data to determine how 80W0 performed against the German Market.

Price Volatility

Is 80W0's price volatile compared to industry and market?
80W0 volatility
80W0 Average Weekly Movement	8.4%
Chemicals Industry Average Movement	5.9%
Market Average Movement	6.0%
10% most volatile stocks in DE Market	13.2%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 80W0 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 80W0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	8	David Palach	www.nexentistech.com

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company’s pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems

Nexentis Technologies Inc. Fundamentals Summary

How do Nexentis Technologies's earnings and revenue compare to its market cap?
80W0 fundamental statistics
Market cap	€3.25m
Earnings (TTM)	-€8.43m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is 80W0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
80W0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$9.81m
Earnings	-US$9.81m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-13.43
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	3.6%

How did 80W0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/27 16:00
End of Day Share Price	2026/05/27 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nexentis Technologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.